Translarna

News
NICE okays neoadjuvant Opdivo in lung cancer

NICE okays neoadjuvant Opdivo in lung cancer

Bristol-Myers Squibb’s Opdivo has become the first immunotherapy to be cleared for NHS use alongside chemotherapy as a pre-surgery (neoadjuvant) therapy for resectable non

News
PTC-Logo

Translarna not approved by NICE for DMD on NHS

In draft guidance published on Friday, it emerged NICE does not recommend PTC Therapeutics’ Translarna (ataluren) for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense

News
Europe delays review of PTC's Duchenne drug

Europe delays review of PTC's Duchenne drug

Doubts have emerged about PTC Therapeutics’ Duchenne muscular dystrophy drug, Translarna (ataluren) after EU regulators delayed a decision on renewing its marketing authorisation.<